Derniers essais

EudraCT Number: 2012-002328-34

Sponsor Protocol Number: KB056

Start Date:

Sponsor Name: KEDRION S.P.A

Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont...

Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	10042613 - Surgical and medical procedures	10067439	Haemostasis	PT

Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2015-003019-39

Sponsor Protocol Number:

Start Date:

Sponsor Name:

Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study

Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	100000004870	10001738	Allergy	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2020-000976-40

Sponsor Protocol Number: ION373-CS1

Start Date:

Sponsor Name: Ionis Pharmaceuticals, Inc

Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand...

Medical condition: Alexander Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	22.1	10010331 - Congenital, familial and genetic disorders	10083059	Alexander disease	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-017477-38

Sponsor Protocol Number: MEK112110

Start Date:

Sponsor Name: GlaxoSmithKline Research & Development Ltd

Full Title: An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Evero...

Medical condition: Solid Tumors

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10059515	Non-small cell lung cancer metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Prematurely Ended)

Trial results: View results

EudraCT Number: 2009-009320-36

Sponsor Protocol Number: 28431754DIA3009

Start Date:

Sponsor Name: Janssen Cilag International NV

Full Title: A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared Wit...

Medical condition: Type 2 Diabetes Mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NO (Completed) DE (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed)

Trial results: View results

EudraCT Number: 2009-015125-36

Sponsor Protocol Number: NCT00934687

Start Date:

Sponsor Name: Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy

Full Title: Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie

Medical condition: Botulinum Toxin for the Treatment of Depression

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2006-000846-38

Sponsor Protocol Number: R076477-BIM-3004

Start Date:

Sponsor Name: Janssen-Cilag International N.V.

Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an ...

Medical condition: Bipolar I disorder, most recent maniac or mixed episode

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.0		10004939		LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2008-005168-15

Sponsor Protocol Number: CQAV680A2201

Start Date:

Sponsor Name: Novartis Pharma Services AG

Full Title: A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placeb...

Medical condition: Mild to moderate persistent asthma, steroid-free patients

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10003553	Asthma	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2018-000127-14

Sponsor Protocol Number: NCT-2017-0516

Start Date:

Sponsor Name: Heidelberg University Hospital

Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies

Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: SE (Ongoing) DE (Ongoing) NL (Ongoing) FR (Ongoing) AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2019-004942-14

Sponsor Protocol Number: IJB-LOB-2019

Start Date:

Sponsor Name: Institut Jules Bordet

Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast

Medical condition: ER-positive/HER2-negative invasive lobular carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073096	Invasive lobular breast carcinoma	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BE (Ongoing)

Trial results: (No results available)

Derniers essais

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue